Miriplatin
![]() | |
Clinical data | |
---|---|
Trade names | Miripla |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C34H68N2O4Pt |
Molar mass | 764.012 g·mol−1 |
3D model (JSmol) | |
| |
|
Miriplatin (INN; trade name Miripla) is a drug used to treat hepatocellular carcinoma (HCC). It is a lipophilic platinum complex that is used in transcatheter arterial chemoembolization (TACE).[1][2] Miriplatin was approved by Japan's Pharmaceuticals and Medical Devices Agency in 2009.[1]
See also[]
References[]
- ^ a b "Miriplatin". Inxight Drugs. National Center for Advancing Translational Sciences, National Institutes of Health.
- ^ Ikeda M, Kudo M, Aikata H, Nagamatsu H, Ishii H, Yokosuka O, et al. (February 2018). "Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial". Journal of Gastroenterology. 53 (2): 281–290. doi:10.1007/s00535-017-1374-6. PMC 5846877. PMID 28766016.
External links[]
Categories:
- Platinum-based antineoplastic agents
- Antineoplastic and immunomodulating drug stubs